Kristin Hostetler
Adult Health · Fernandina Beach, FLNPI 1609156470
Payments from drug & device makers
Across 257 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$483
- Boehringer Ingelheim$467
- Pfizer$394
- Johnson & Johnson$369
- Novartis$368
- Novo Nordisk$331
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,541100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $483 |
| Boehringer Ingelheim | 22 | $467 |
| Pfizer | 19 | $394 |
| Johnson & Johnson | 21 | $369 |
| Novartis | 20 | $368 |
| Novo Nordisk | 22 | $331 |
| Amgen | 14 | $320 |
| Merck | 14 | $255 |
| AstraZeneca | 10 | $243 |
| Bayer | 12 | $211 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $196 |
| Stryker | 1 | $169 |
| Painteq LLC | 2 | $150 |
| Corcept Therapeutics | 2 | $144 |
| Idorsia Pharmaceuticals US Inc | 5 | $142 |
| Boston Scientific | 1 | $139 |
| Medtronic | 2 | $121 |
| E.r. Squibb & Sons, L.L.C. | 7 | $113 |
| Exact Sciences | 7 | $112 |
| Cvrx, Inc. | 2 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $103 |
| GSK | 5 | $97 |
| Amarin Pharma, Inc. | 3 | $61 |
| AbbVie | 3 | $59 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Abiomed | 1 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Halozyme Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,541 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 58 | $61,788 |
| EliquisApixaban | 37 | $39,692 |
| OzempicSemaglutide | 28 | $33,722 |
| JardianceEmpagliflozin | 36 | $33,103 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $28,046 |
| MyrbetriqMirabegron | 33 | $17,156 |
| FarxigaDapagliflozin Propanediol | 14 | $10,209 |
| Repatha PushtronexEvolocumab | 12 | $9,526 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,461 |
| Estradiol | 62 | $3,172 |
| Rosuvastatin Calcium | 253 | $2,526 |
| Losartan Potassium | 191 | $2,284 |
| Levothyroxine Sodium | 146 | $1,476 |
| Famotidine | 81 | $1,276 |
| SynthroidLevothyroxine Sodium | 13 | $1,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $483 | $61,78858 claims |
| PfizerEliquis | $394 | $39,69237 claims |
| Novo NordiskOzempic | $331 | $33,72228 claims |
| Boehringer IngelheimJardiance | $467 | $33,10336 claims |
| GSKTrelegy Ellipta | $97 | $28,04631 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $243 | $18,67027 claims |
| Astellas Pharma US IncMyrbetriq | $15 | $17,15633 claims |
| AbbVieSynthroid | $59 | $1,26313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.
Other adult health in Fernandina Beach
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.